China Plans Clinical Data Protection By Product Category For First Time
Up To Six Years For Novel Small Molecules, Biologics
After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.
